CRL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Charles River Laboratories International Inc (CRL) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock shows mixed signals with no strong upward momentum or significant positive catalysts to justify immediate investment. Holding off for now is the most prudent action.
The MACD is positive and expanding, indicating a potential bullish trend. However, RSI is neutral at 69.804, and moving averages are converging, showing no clear trend. The stock price is currently trading below the pivot level (164.951), and key resistance levels (R1: 176.031, R2: 182.876) are not yet breached.
The MACD histogram is positive and expanding, which could indicate potential upward momentum. Gross margin increased significantly in the latest quarter, showing operational efficiency improvement.
Revenue declined YoY by 0.83%, and while net income improved, it remains negative at -276.555 million. Analyst ratings have been largely neutral or with reduced price targets, citing slower organic growth and lower free cash flow. No recent news or significant insider/hedge fund activity to drive sentiment.
In Q4 2025, revenue dropped by 0.83% YoY to $994.227 million. However, net income improved by 28.21% YoY but remains negative at -$276.555 million. EPS increased by 33.18% YoY to -5.62, and gross margin improved by 11.49% YoY to 30.96%.
Analyst ratings are mixed with several firms lowering price targets recently. UBS and Mizuho maintain neutral ratings with price targets at $175, while TD Cowen, Evercore ISI, and Baird remain optimistic with higher targets but have also reduced their expectations. Concerns about slower organic growth and AI's impact on the industry weigh on sentiment.
